Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27
Filter
1.
Intern Med ; 62(21): 3251-3254, 2023 Nov 01.
Article in English | MEDLINE | ID: mdl-36927972

ABSTRACT

An 80-year-old woman with rheumatoid arthritis during treatment with etanercept, a tumor necrosis factor (TNF) inhibitor, showed swelling of the salivary glands and retroperitoneal fibrosis, which was diagnosed as IgG4-related disease. Although some reports have shown the efficacy of TNF inhibitors for IgG4-related disease or retroperitoneal fibrosis, TNF inhibitors sometimes cause paradoxical reactions like psoriasis, and the mechanisms are considered to involve the upregulation of plasmacytoid dendritic cells and IFN-α, which is also common in patients with IgG4-related disease. This is a case report of IgG4-related retroperitoneal fibrosis with the possibility of a rare paradoxical reaction by a TNF inhibitor.


Subject(s)
Arthritis, Rheumatoid , Immunoglobulin G4-Related Disease , Retroperitoneal Fibrosis , Female , Humans , Aged, 80 and over , Tumor Necrosis Factor Inhibitors , Retroperitoneal Fibrosis/chemically induced , Retroperitoneal Fibrosis/drug therapy , Retroperitoneal Fibrosis/diagnosis , Immunoglobulin G/adverse effects , Arthritis, Rheumatoid/drug therapy
2.
Ann Rheum Dis ; 82(5): 621-629, 2023 05.
Article in English | MEDLINE | ID: mdl-36627170

ABSTRACT

OBJECTIVES: Prevotella copri is considered to be a contributing factor in rheumatoid arthritis (RA). However, in some non-Westernised countries, healthy individuals also harbour an abundance of P. copri in the intestine. This study investigated the pathogenicity of RA patient-derived P. copri (P. copri RA) compared with healthy control-derived P. copri (P. copri HC). METHODS: We obtained 13 P. copri strains from the faeces of patients with RA and healthy controls. Following whole genome sequencing, the sequences of P. copri RA and P. copri HC were compared. To analyse the arthritis-inducing ability of P. copri, we examined two arthritis models (1) a collagen-induced arthritis model harbouring P. copri under specific-pathogen-free conditions and (2) an SKG mouse arthritis model under P. copri-monocolonised conditions. Finally, to evaluate the ability of P. copri to activate innate immune cells, we performed in vitro stimulation of bone marrow-derived dendritic cells (BMDCs) by P. copri RA and P. copri HC. RESULTS: Comparative genomic analysis revealed no apparent differences in the core gene contents between P. copri RA and P. copri HC, but pangenome analysis revealed the high genome plasticity of P. copri. We identified a P. copri RA-specific genomic region as a conjugative transposon. In both arthritis models, P. copri RA-induced more severe arthritis than P. copri HC. In vitro BMDC stimulation experiments revealed the upregulation of IL-17 and Th17-related cytokines (IL-6, IL-23) by P. copri RA. CONCLUSION: Our findings reveal the genetic diversity of P. copri, and the genomic signatures associated with strong arthritis-inducing ability of P. copri RA. Our study contributes towards elucidation of the complex pathogenesis of RA.


Subject(s)
Arthritis, Rheumatoid , Gastrointestinal Microbiome , Animals , Mice , Gastrointestinal Microbiome/genetics , Arthritis, Rheumatoid/genetics , Prevotella/genetics , Genomics , Disease Models, Animal
3.
Ann Otol Rhinol Laryngol ; 132(6): 709-714, 2023 Jun.
Article in English | MEDLINE | ID: mdl-35833237

ABSTRACT

OBJECTIVES: Although some patients with postviral olfactory dysfunction (PVOD) recover spontaneously, many others are left with the degree of smell loss and there are no established drugs for the treatment of patients with PVOD. Valproic acid (VPA) has been widely used for the treatment of epilepsy. Its potential neuroregenerative effects have been shown via animal studies. This is the first study to treat PVOD patients with VPA. This open-label, single-arm, phase II study was conducted to investigate the effects of VPA in patients with PVOD. METHODS: The patients received oral tablets of VPA 200 mg twice a day for 24 weeks. In total, 11 patients with PVOD were recruited. Oder scores of recognition and detection threshold (measured with a T&T olfactometer), and visual analog scale were examined during the treatment. RESULTS: All odor scores significantly improved over time. Although the mean duration of olfactory dysfunction in this study was 11.5 months, both odor recognition threshold and odor detection threshold scores significantly improved 4 weeks after treatment initiation compared to the pre-treatment threshold scores. The olfactory recovery rates in patients treated with VPA were clearly better than those we previously reported in PVOD patients who received Toki-shakuyaku-san, the traditional treatment in Japan. The olfactory recovery rates of patients with PVOD at 12 weeks and 24 weeks of VPA treatment were both 77.8%, and the olfactory cure rates at 12 weeks and 24 weeks of VPA treatment were 33.3% and 44.4%, respectively. No serious adverse events were observed. CONCLUSIONS: VPA seems to be a safe treatment option in patients with PVOD. The effects of VPA treatment for PVOD patients should be studied with a controlled study design in the future.


Subject(s)
Olfaction Disorders , Valproic Acid , Animals , Valproic Acid/therapeutic use , Olfaction Disorders/drug therapy , Olfaction Disorders/etiology , Pilot Projects , Smell , Anosmia
4.
ACS Med Chem Lett ; 12(9): 1464-1469, 2021 Sep 09.
Article in English | MEDLINE | ID: mdl-34531955

ABSTRACT

The absolute structure of an indole alkaloid (+)-cinchonaminone by total synthesis of both (+)-cinchonaminone and its enantiomer was determined. The main focus of the study was the enantioselective synthesis of both enantiomers of a chiral cis-3,4-disubstituted piperidine. We also evaluated monoamine oxidase (MAO) inhibitory activities of these enantiomers. Furthermore, its structurally simplified derivatives were synthesized that did not have any chiral center. Two of these derivatives showed stronger MAO inhibitory activities than that of (+)-cinchonaminone.

5.
Biochem Biophys Res Commun ; 534: 540-546, 2021 01 01.
Article in English | MEDLINE | ID: mdl-33239174

ABSTRACT

Nanoparticles, i.e., particles with a diameter of ≤100 nm regardless of their composing material, are added to various foods as moisturizers, coloring agents, and preservatives. Silicon dioxide (SiO2, silica) nanoparticles in particular are widely used as food additives. However, the influence of SiO2 nanoparticle oral consumption on intestinal homeostasis remains unclear. The daily intake of 10-nm-sized SiO2 nanoparticles exacerbates dextran sulfate sodium (DSS)-induced colitis, whereas the daily intake of 30-nm-sized SiO2 nanoparticles has no influence on intestinal inflammation. The exacerbation of colitis induced by consuming 10-nm-sized SiO2 nanoparticles was abolished in mice deficient in apoptosis-associated speck-like protein containing a CARD (ASC). Our study indicates that the oral intake of small SiO2 nanoparticles poses a risk for worsening intestinal inflammation through activation of the ASC inflammasome.


Subject(s)
Colitis/pathology , Food Additives/adverse effects , Inflammation/pathology , Nanoparticles/adverse effects , Silicon Dioxide/adverse effects , Administration, Oral , Animals , Colitis/chemically induced , Dextran Sulfate , Food Additives/administration & dosage , Inflammasomes/analysis , Inflammation/chemically induced , Intestines/pathology , Male , Mice, Inbred C57BL , Nanoparticles/administration & dosage , Particle Size , Silicon Dioxide/administration & dosage
6.
Ann Otol Rhinol Laryngol ; 129(10): 977-982, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32456451

ABSTRACT

OBJECTIVES: The aims of the present study were to clarify the time-course of olfactory recovery and the prognostic factors in PIOD patients treated with Toki-shakuyaku-san (TSS). METHODS: A retrospective cohort study of patients with PIOD was conducted by reviewing patients' medical records. This study included patients who received TSS or a combination of TSS and zinc sulfate. Olfactory function was examined by T&T olfactometer at each 3-monthly follow-up visit. Patients with normal and mild olfactory dysfunction were excluded. Gender, age, treatment, duration of disease until the first visit and olfactory function scores of the T&T olfactometer at the first visit were analyzed as candidate clinical predictors of recovery. RESULTS: A total of 82 PIOD patients with ages ranging from 16 to 79 years were included. The mean duration of follow-up was 14.5 months (range 3-45 months). The number of patients with olfactory recovery increased for 24 months and the cumulative recovery rate was 77.3%. In about 60% of patients, olfactory recovery occurred within 6 months. Multivariate analysis showed that younger age (<65 years) and residual olfactory function were significantly associated with good olfactory recovery. CONCLUSIONS: We revealed recovery rates over time in patients with PIOD. The recovery of olfactory function often occurred during the early period (≤6 months). However, the number of patients with olfactory recovery increased for a long-term of 24 months after the first visit. Residual olfactory function and younger age were prognostic factors exactly. TSS may be a useful therapeutic agent for patients with PIOD. We believe that these results provide important information that is useful for counseling patients with PIOD.


Subject(s)
Drugs, Chinese Herbal/therapeutic use , Olfaction Disorders/drug therapy , Recovery of Function , Respiratory Tract Infections/complications , Zinc Sulfate/therapeutic use , Adolescent , Adult , Age Factors , Aged , Humans , Middle Aged , Olfaction Disorders/etiology , Olfaction Disorders/physiopathology , Prognosis , Retrospective Studies , Time Factors , Young Adult
7.
Clin Exp Dent Res ; 6(4): 420-427, 2020 08.
Article in English | MEDLINE | ID: mdl-32281236

ABSTRACT

BACKGROUND: Ezrin, ERK, STAT3, and AKT are proteins that are overexpressed in various types of cancer, although their expressions in tongue cancer has received less focus. This study aimed to address associations between the expression levels of these proteins and with characteristics of the tumor and patient survival. METHODS: We performed immunohistochemical staining of ezrin, ERK, STAT3, and AKT in tumors from patients with tongue carcinoma in situ (CIS, n = 17) and tongue squamous cell carcinoma (SCC, n = 46). Statistical differences between the SCC versus the CIS cohorts were estimated by calculations of bivariate odds ratios of low versus high expression of the proteins. Fisher's exact tests were used to appraise interassociations between the proteins, as well as expression levels versus patient and tumor characteristics. Survival based on Kaplan-Meier statistics in combination log-rank tests were used to address potential effects of the patient and tumor characteristics versus 5-year survival rate. RESULTS: The relative high: low expression of all four proteins in the two cohorts differed, and particularly ERK was markedly overexpressed in the SCC versus the CIS cohort (odds ratio = 45.3, p < .01). The relative high: low expression each protein versus patient and tumor characteristics; showed associations between AKT expression and T stage (p = .002) plus node metastases (p = .12), and between ERK expression and drinking (p = .01) and smoking history (p = .01). There was no significant difference observed between ERK and the three other molecules, nor any significant difference between the degree of expression of each protein and the 5-year disease-specific survival rate. CONCLUSION: Ezrin, ERK, STAT3, and AKT appear to be involved in the progress from carcinoma in situ in the tongue into squamous cell carcinoma. ERK in particular is overexpressed, suggesting that ERK may be a novel therapeutic target for preventing tongue cancer.


Subject(s)
Biomarkers, Tumor/metabolism , Cytoskeletal Proteins/metabolism , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Proto-Oncogene Proteins c-akt/metabolism , STAT3 Transcription Factor/metabolism , Tongue Neoplasms/mortality , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prognosis , Survival Rate , Tongue Neoplasms/metabolism , Tongue Neoplasms/pathology , Tongue Neoplasms/surgery
8.
NPJ Biofilms Microbiomes ; 5(1): 37, 2019.
Article in English | MEDLINE | ID: mdl-31885873

ABSTRACT

The bacterial species living in the gut mediate many aspects of biological processes such as nutrition and activation of adaptive immunity. In addition, commensal fungi residing in the intestine also influence host health. Although the interaction of bacterium and fungus has been shown, its precise mechanism during colonization of the human intestine remains largely unknown. Here, we show interaction between bacterial and fungal species for utilization of dietary components driving their efficient growth in the intestine. Next generation sequencing of fecal samples from Japanese and Indian adults revealed differential patterns of bacterial and fungal composition. In particular, Indians, who consume more plant polysaccharides than Japanese, harbored increased numbers of Prevotella and Candida. Candida spp. showed strong growth responses to the plant polysaccharide arabinoxylan in vitro. Furthermore, the culture supernatants of Candida spp. grown with arabinoxylan promoted rapid proliferation of Prevotella copri. Arabinose was identified as a potential growth-inducing factor in the Candida culture supernatants. Candida spp. exhibited a growth response to xylose, but not to arabinose, whereas P. copri proliferated in response to both xylose and arabinose. Candida spp., but not P. copri, colonized the intestine of germ-free mice. However, P. copri successfully colonized mouse intestine already harboring Candida. These findings demonstrate a proof of concept that fungal members of gut microbiota can facilitate a colonization of the intestine by their bacterial counterparts, potentially mediated by a dietary metabolite.


Subject(s)
Bacteria/growth & development , Bacteria/metabolism , Diet/methods , Fungi/growth & development , Fungi/metabolism , Gastrointestinal Microbiome , Microbial Interactions , Animals , Bacteria/classification , Feces/microbiology , Fungi/classification , Humans , India , Japan , Mice , Models, Animal , Polysaccharides/metabolism
9.
Auris Nasus Larynx ; 46(5): 653-662, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31076272

ABSTRACT

OBJECTIVE: To provide an evidence-based recommendation for the management of olfactory dysfunction in accordance with the consensus reached by the Subcommittee of the Japanese Clinical Practice Guideline for olfactory dysfunction in the Japanese Rhinologic Society. METHODS: Seven clinical questions (CQs) regarding the management of olfactory dysfunction were formulated by the subcommittee of the Japanese Clinical Practice Guideline for olfactory dysfunction. We searched the literature published between April 1990 and September 2014 using PubMed, the Cochrane Library, and Ichushi Web databases. The main search terms were "smell disorder," "olfactory dysfunction," "olfactory loss," "olfactory disturbance," "olfactory impairments," "olfaction disorder," "smell disorder," "anosmia," "cacosmia," and "dysosmia." Based on the results of the literature review and the expert opinion of the Subcommittee, 4 levels of recommendation, from A-strongly recommended to D-not recommended, were adopted for the management of olfactory dysfunction. RESULTS: Both oral and locally administered corticosteroids have been strongly recommended for patients with olfactory dysfunction due to chronic rhinosinusitis. Nasal steroid spray and antihistamine drugs have been moderately recommended for patients with allergic rhinitis. Although no drugs have been deemed to be truly effective for post-viral olfactory dysfunction by randomized-controlled trials (RCTs) or placebo-controlled trials, olfactory training using odorants has been reported to be effective for improving olfactory function. There is considerable evidence that olfactory testing is useful for differential diagnosis, prediction of disease progression, and early detection of cognitive decline in neurodegenerative diseases. CONCLUSION: The Clinical Practice Guideline has developed recommendations for the management of various aspects of olfactory dysfunction.


Subject(s)
Olfaction Disorders/therapy , Adrenal Cortex Hormones/therapeutic use , Chronic Disease , Histamine Antagonists/therapeutic use , Humans , Japan , Neurodegenerative Diseases/complications , Olfaction Disorders/diagnosis , Olfaction Disorders/etiology , Otolaryngology , Otorhinolaryngologic Surgical Procedures , Prognosis , Rhinitis/complications , Sensory Thresholds , Sinusitis/complications , Societies, Medical
10.
Clin Immunol ; 188: 1-6, 2018 03.
Article in English | MEDLINE | ID: mdl-29183867

ABSTRACT

Mucus hypersecretion and eosinophil infiltration are important characteristics of eosinophilic inflammation in upper airways, such as allergic rhinitis and chronic rhinosinusitis with nasal polyp. EGFR transactivation induces mucus and inflammatory cytokine secretion from airway epithelial cells. However, the roles of EGFR in eosinophilic inflammation in upper airways are still unknown. The purpose of the study is to elucidate the effects of the EGFR inhibitor AG1478 on eosinophilic airway inflammation. AG1478 significantly inhibited thrombin-induced GM-CSF secretion from nasal epithelial cells and thrombin-induced secretion of eotaxin-1 and RANTES from nasal fibroblasts. Intranasal instillation of AG1478 inhibited OVA-induced goblet cell metaplasia, mucus production and eosinophil/neutrophil infiltration in rat nasal epithelium, as did intraperitoneal injection of AG1478. These results indicate that EGFR transactivation plays an important role in eosinophilic airway inflammation. Intranasal instillation of an EGFR inhibitor may be a new therapeutic approach for the treatment of intractable eosinophilic inflammation in upper airways.


Subject(s)
Eosinophils/drug effects , ErbB Receptors/antagonists & inhibitors , Inflammation/prevention & control , Quinazolines/pharmacology , Respiratory Mucosa/drug effects , Tyrphostins/pharmacology , Administration, Intranasal , Animals , Cells, Cultured , Chemokine CCL11/metabolism , Chemokine CCL5/metabolism , Enzyme Inhibitors/administration & dosage , Enzyme Inhibitors/pharmacology , Eosinophilia/metabolism , Eosinophilia/prevention & control , Eosinophils/metabolism , Eosinophils/pathology , Epithelial Cells/drug effects , Epithelial Cells/metabolism , ErbB Receptors/metabolism , Granulocyte-Macrophage Colony-Stimulating Factor/metabolism , Humans , Inflammation/metabolism , Nasal Mucosa/drug effects , Nasal Mucosa/metabolism , Nasal Mucosa/pathology , Neutrophil Infiltration/drug effects , Quinazolines/administration & dosage , Rats , Respiratory Mucosa/metabolism , Respiratory Mucosa/pathology , Thrombin/pharmacology , Tyrphostins/administration & dosage
11.
Auris Nasus Larynx ; 45(2): 362-366, 2018 Apr.
Article in English | MEDLINE | ID: mdl-28511889

ABSTRACT

We herein present three cases of abnormally expanded frontal sinuses (pneumoceles) with severe infection in patients with mental retardation and brain atrophy. Two patients previously underwent laryngotracheal separation surgery, and bacteriological examinations of purulent nasal discharge revealed infections caused by drug-resistant bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii. As conservative medical treatments were ineffective, all three patients were treated by computed tomography-guided endoscopic sinus surgery. This navigation system is useful for safer surgery in the area of anatomic deformity. The clinical findings, possible etiologies and surgical treatment of these cases are discussed.


Subject(s)
Abscess/surgery , Frontal Sinus/surgery , Frontal Sinusitis/surgery , Orbital Cellulitis/surgery , Abscess/complications , Abscess/diagnostic imaging , Acinetobacter Infections/complications , Acinetobacter Infections/diagnostic imaging , Acinetobacter Infections/surgery , Acinetobacter baumannii , Adult , Aged , Atrophy , Brain/diagnostic imaging , Brain/pathology , Citrobacter koseri , Endoscopy , Enterobacteriaceae Infections/complications , Enterobacteriaceae Infections/diagnostic imaging , Enterobacteriaceae Infections/surgery , Female , Fever , Frontal Sinus/diagnostic imaging , Frontal Sinusitis/complications , Frontal Sinusitis/diagnostic imaging , Humans , Intellectual Disability/complications , Male , Moraxella catarrhalis , Moraxellaceae Infections/complications , Moraxellaceae Infections/diagnostic imaging , Moraxellaceae Infections/surgery , Orbital Cellulitis/complications , Orbital Cellulitis/diagnostic imaging , Paranasal Sinus Diseases/complications , Paranasal Sinus Diseases/diagnostic imaging , Paranasal Sinus Diseases/surgery , Pseudomonas Infections/complications , Pseudomonas Infections/diagnostic imaging , Pseudomonas Infections/surgery , Pseudomonas aeruginosa , Subcutaneous Tissue , Surgery, Computer-Assisted , Tomography, X-Ray Computed , Young Adult
12.
Auris Nasus Larynx ; 44(2): 168-173, 2017 Apr.
Article in English | MEDLINE | ID: mdl-27427537

ABSTRACT

OBJECTIVE: Alzheimer-type dementia (AD) is pathologically characterized by massive neuronal loss in the brain, and the taste cortex is thought to be affected. However, there are only a few reports regarding the gustatory function of AD patients, and the conclusions of this research are inconsistent. METHODS: This prospective study enrolled 22 consecutive patients with mild to moderately severe Alzheimer-type dementia (AD) with mean age of 84.0 years, and 49 elderly volunteers without dementia with mean age of 71.0 years as control subjects. The control subjects were divided into two groups according to age: a younger group (N=28, mean age: 68.5) and an older group (N=21, mean age: 83.0). The gustatory function was investigated using the filter paper disc method (FPD) and electrogustometry (EGM). RESULTS: The gustatory function as measured by the FPD was significantly impaired in patients with AD as compared with age-matched control subjects; no such difference was found between the younger and the older control groups. On the other hand, as for the EGM thresholds, there were no differences between the AD patient group and the age-matched controls. CONCLUSION: The FPD method demonstrated decreased gustatory function in AD patients beyond that of aging. On the other hand, EGM thresholds did not differ between the AD patient group and the age-matched controls. These results suggest that failure of taste processing in the brain, but not taste transmission in the peripheral taste system, occurs in patients with AD.


Subject(s)
Aging/physiology , Alzheimer Disease/physiopathology , Perceptual Disorders/physiopathology , Taste Disorders/physiopathology , Taste Perception , Taste , Aged , Aged, 80 and over , Case-Control Studies , Female , Humans , Japan , Male , Middle Aged , Prospective Studies , Taste Threshold
13.
Clin Immunol ; 170: 1-8, 2016 09.
Article in English | MEDLINE | ID: mdl-27422491

ABSTRACT

ILC2s represent a critical innate cellular source of type 2 cytokines and may play important roles in various diseases. We examined the role of ILC2s in the pathogenesis of two subgroups of CRSwNP: ECRS and non-ECRS. We analyzed the prevalence of ILC2s in sinonasal tissues and in blood from patients with ECRS, non-ECRS, CRSsNP, and control. The prevalence of ILC2s in nasal tissues was higher in patients with ECRS as compared to those with non-ECRS or CRSsNP. The prevalence of blood ILC2s was not different between patients with ECRS and non-ECRS. The prevalence of blood ILC2s was higher in patients with allergic rhinitis and elevated serum IgE levels. Alternaria-induced IL-33 secretion was increased in nasal epithelial cells derived from patients with ECRS as compared to those from patients with non-ECRS or CRSsNP. ILC2s may be involved in the pathogenesis of CRSwNP, in particular in patients with tissue eosinophilia (i.e., ECRS).


Subject(s)
Cytokines/immunology , Lymphocytes/immunology , Nasal Polyps/immunology , Rhinitis/immunology , Sinusitis/immunology , Adult , Alternaria/chemistry , Alternaria/immunology , Cells, Cultured , Chronic Disease , Cytokines/metabolism , Enzyme-Linked Immunosorbent Assay , Eosinophils/immunology , Eosinophils/metabolism , Epithelial Cells/immunology , Epithelial Cells/metabolism , Female , Flow Cytometry , Humans , Immunity, Innate/immunology , Interleukin-33/immunology , Interleukin-33/metabolism , Lymphocyte Count , Lymphocytes/metabolism , Male , Middle Aged , Nasal Mucosa/immunology , Nasal Mucosa/metabolism , Nasal Polyps/blood , Nasal Polyps/metabolism , Rhinitis/blood , Rhinitis/metabolism , Sinusitis/blood , Sinusitis/metabolism
14.
Am J Rhinol Allergy ; 30(1): 1-6, 2016.
Article in English | MEDLINE | ID: mdl-26867523

ABSTRACT

BACKGROUND: Mucus hypersecretion and neutrophil infiltration are important characteristics of airway inflammation. Epidermal growth factor receptor (EGFR) transactivation induces mucus and inflammatory cytokine secretion from airway epithelial cells. To elucidate the roles of EGFR in airway inflammation, the in vitro effects on mucin production and interleukin (IL) 8 secretion from cultured airway epithelial cells and the in vivo effects on mucus hypersecretion and neutrophil infiltration in rat nasal mucosa of the EGFR tyrosine kinase inhibitor AG1478 were examined. METHODS: The in vitro effects of AG1478 treatment of cultured NCI-H292 cells on lipopolysaccharide (LPS) induced or tumor necrosis factor (TNF) α induced MUC5AC mucin and IL-8 secretion were evaluated. Hypertrophic and metaplastic changes of goblet cells, mucus production and neutrophil infiltration in rat nasal epithelium were induced by intranasal instillation of LPS in vivo, and the inhibitory effects of AG1478 by intraperitoneal injection or intranasal instillation were examined. RESULTS: AG1478 (1-1000 nM) significantly inhibited both LPS-induced and TNF-α-induced secretion of MUC5AC and IL-8 from cultured NCI-H292 cells in a dose-dependent manner. The expression of MUC5AC and IL-8 messenger RNAs was also significantly inhibited. Intranasal instillation of AG1478 one hour after intranasal LPS instillation significantly inhibited LPS-induced goblet cell metaplasia, mucus production, and neutrophil infiltration in rat nasal epithelium, as did intraperitoneal injection of AG1478 one hour before LPS instillation. CONCLUSIONS: These results indicated that EGFR transactivation plays an important role in mucin and IL-8 secretion from airway epithelial cells. Intranasal instillation of an EGFR tyrosine kinase inhibitor may be a new therapeutic approach for the treatment of upper airway inflammation.


Subject(s)
Interleukin-8/metabolism , Mucin 5AC/metabolism , Mucus/metabolism , Neutrophils/drug effects , Pneumonia/drug therapy , Quinazolines/therapeutic use , Respiratory Mucosa/drug effects , Tyrphostins/therapeutic use , Animals , Cell Line, Tumor , ErbB Receptors/antagonists & inhibitors , Gene Expression Regulation/drug effects , Humans , Interleukin-8/genetics , Male , Mucin 5AC/genetics , Neutrophils/immunology , Quinazolines/pharmacology , Rats , Rats, Inbred F344 , Respiratory Mucosa/physiology , Tyrphostins/pharmacology
15.
Nihon Jibiinkoka Gakkai Kaiho ; 118(8): 1016-26, 2015 Aug.
Article in Japanese | MEDLINE | ID: mdl-26548095

ABSTRACT

The clinical characteristics of 16 patients with congenital anosmia were examined retrospectively. MRI (magnetic resonance imaging) was used to assess the morphological changes in the olfactory bulbs and olfactory sulci according to the method of P. Rombaux (2009). Congenital anosmia was divided into two forms: syndromic forms in association with a syndrome, and isolated forms without evidence of other defects. Only three patients (19%) in our series had syndromic forms of congenital anosmia, such as the Kallmann syndrome. Most cases (13 patients, 81%) had isolated congenital anosmia. Psychophysical testing of the olfactory function included T&T olfactometry and the intravenous Alinamin test, which are widely used in Japan. In T&T olfactometry, detection and recognition thresholds for the five odorants are used to assign a diagnostic category representing the level of olfactory function. Most cases (14 patients, 88%) showed off-scale results on T&T olfactometry, and the Alinamin test resulted in no response in all 11 patients who underwent the test. Abnormal MRI findings of the olfactory bulbs and sulci were detected in 15 of 16 patients (94%). Olfactory bulbs were bilaterally absent in nine patients (56%), and two patients (13%) had unilateral olfactory bulbs. Four patients (25%) had bilateral hypoplastic olfactory bulbs, and only one patient had normal olfactory bulbs (6%). The olfactory sulcus was unilaterally absent in one patient (6%), and nine patients (56%) had bilaterally hypoplastic olfactory sulci. Two patients (13%) had a unilateral normal olfactory sulcus and hypoplastic olfactory sulcus. Three patients (19%) had normal olfactory sulci. Quantitative analysis showed that the volume of olfactory bulbs varied from 0 mm3 to 63.5 mm3, with a mean volume of 10.20 ± 18 mm3, and the mean depth of the olfactory sulcus varied from 0 mm to 12.22 mm, with a mean length of 4.85 ± 4.1 mm. Currently, there is no effective treatment for congenital anosmia. However, diagnosis of congenital anosmia is important, as its presence can lead to dangerous situations. Careful examination for hypogonadism is also required in people with anosmia. MRI examinations of the olfactory bulbs and sulci were useful for the diagnosis of congenital anosmia.


Subject(s)
Magnetic Resonance Imaging , Olfaction Disorders/congenital , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Humans , Japan , Male , Middle Aged , Olfaction Disorders/diagnosis , Olfaction Disorders/drug therapy , Retrospective Studies , Surveys and Questionnaires , Thiamine/analogs & derivatives , Thiamine/therapeutic use , Young Adult
16.
Am J Rhinol Allergy ; 29(4): 235-42, 2015.
Article in English | MEDLINE | ID: mdl-26163243

ABSTRACT

BACKGROUND: Activation of the coagulation system with an increase in thrombin generation is involved in the pathogenesis of tissue remodeling in chronic rhinosinusitis (CRS). Tissue factor (TF) is an important protein for initiation of the extrinsic coagulation pathway, and TF pathway inhibitor (TFPI) is a regulator of TF-induced coagulation. This study was conducted to elucidate the roles of TF and TFPI in the pathogenesis of CRS. METHODS: Tissue localization of TF, TFPI, and fibrin was determined by immunostaining of nasal polyps and inferior turbinates obtained during endonasal surgery in patients with CRS with nasal polyp (CRSwNP). Nasal secretions were collected from patients with CRSwNP, allergic rhinitis, and from control patients. The concentrations of TF and TFPI were measured in nasal secretions from each group. The concentrations of TF and TFPI released into culture medium by normal human nasal epithelial cells treated with thrombin, protease-activated receptor 1 agonist peptide, or tumor necrosis factor α were also measured. RESULTS: TF expression was localized in nasal epithelial cells and in infiltrating eosinophils of nasal mucosa. TFPI expression was localized in nasal epithelial cells, and fibrin deposition was observed in nasal secretions and the lamina propria of nasal polyps. Nasal secretions contained significant concentrations of TF and TFPI. The concentration of TFPI in nasal secretions correlated positively with thrombin activity and the concentration of thrombin-antithrombin III complex. Treatment with thrombin, protease-activated receptor 1 agonist peptide, or tumor necrosis factor α stimulated significant release of TF and TFPI from cultured nasal epithelial cells. CONCLUSIONS: By upregulating the coagulation system, TF and TFPI play an important role in the pathogenesis of CRSwNP.


Subject(s)
Lipoproteins/genetics , Nasal Mucosa/metabolism , Nasal Polyps/genetics , Rhinitis/genetics , Sinusitis/genetics , Thromboplastin/genetics , Up-Regulation/genetics , Adult , Aged , Antithrombin III/metabolism , Cells, Cultured , Chronic Disease , Eosinophils/cytology , Epithelial Cells , Female , Genetic Markers/genetics , Hemostatics/metabolism , Humans , Immunoglobulin E/blood , Immunohistochemistry , In Vitro Techniques , Male , Middle Aged , Mucins/metabolism , Nasal Mucosa/pathology , Nasal Polyps/diagnosis , Nasal Polyps/metabolism , Peptide Hydrolases/metabolism , Predictive Value of Tests , Rhinitis/diagnosis , Rhinitis/metabolism , Sensitivity and Specificity , Sinusitis/diagnosis , Sinusitis/metabolism , Thrombin/metabolism
17.
Auris Nasus Larynx ; 42(4): 332-6, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25769240

ABSTRACT

OBJECTIVE: Low-dose, long-term use of 14-membered macrolides is effective for treatment of patients with chronic airway inflammation such as diffuse panbronchiolitis or chronic rhinosinusitis. However, long-term use of macrolides can promote the growth of drug-resistant bacteria, and the development of anti-inflammatory macrolides that lack antibiotic effects is desirable. Previously, we developed EM900, a novel 12-membered erythromycin A derivative, which has potent anti-inflammatory and immunomodulatory activities and lacks any antibacterial activity. We examined the anti-inflammatory effects of EM900 on mucus secretion from airway epithelial cells. METHODS: To examine the in vivo effects of EM900 on airway inflammation, we induced hypertrophic and metaplastic changes of goblet cells in rat nasal epithelium via intranasal instillation of lipopolysaccharides. In vitro effects of EM900 on airway epithelial cells were examined using cultured human airway epithelial (NCI-H292) cells. Mucus secretion was evaluated via enzyme-linked immunosorbent assays with an anti-MUC5AC monoclonal antibody. RESULTS: Oral administration of EM900 or clarithromycin (CAM) significantly inhibited LPS-induced mucus production from rat nasal epithelium. EM900, CAM, or erythromycin significantly inhibited MUC5AC secretion induced by tumor necrosis factor-α from NCI-H292 cells. MUC5AC mRNA expression was also significantly lower in EM900-treated cells. CONCLUSION: These results indicated that a novel non-antibiotic macrolide, EM900 exerted direct inhibitory effects on mucus secretion from airway epithelial cells, and that it may have the potential to become a new anti-inflammatory drug for the treatment of chronic rhinosinusitis.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Erythromycin/analogs & derivatives , Goblet Cells/drug effects , Mucus/drug effects , Nasal Mucosa/drug effects , RNA, Messenger/drug effects , Animals , Anti-Bacterial Agents/pharmacology , Cells, Cultured , Clarithromycin/pharmacology , Erythromycin/pharmacology , Goblet Cells/metabolism , Humans , In Vitro Techniques , Lipopolysaccharides/pharmacology , Mucin 5AC/drug effects , Mucin 5AC/genetics , Mucin 5AC/metabolism , Mucus/metabolism , Nasal Mucosa/metabolism , RNA, Messenger/metabolism , Rats , Respiratory Mucosa/drug effects , Respiratory Mucosa/metabolism , Tumor Necrosis Factor-alpha/pharmacology
18.
Am J Rhinol Allergy ; 28(2): e95-9, 2014.
Article in English | MEDLINE | ID: mdl-24717941

ABSTRACT

BACKGROUND: Recent experiments have revealed that valproic acid (VPA), a histone deacetylase inhibitor, has neuroregenerative effects in rodent models of spinal cord and optic nerve injury. VPA has a potential to provide a new therapeutic strategy for sensorineural olfactory dysfunction. To elucidate the effects of VPA on regeneration of olfactory sensory neurons, we examined the in vivo effects of oral VPA administration on recovery from methimazole-induced degeneration of olfactory neuroepithelium in mice. METHODS: Male ICR mice (10 weeks old) were intraperitoneally injected with methimazole (75 mg/kg), an olfactory toxic reagent, to induce degenerative changes in the olfactory neuroepithelium. The effects of daily VPA administration on recovery from methimazole-induced changes were examined histologically. RESULTS: Oral VPA administration dose dependently enhanced increases in epithelial thickness and number of olfactory marker protein (OMP) positive cells in the olfactory epithelium during recovery from methimazole-induced degeneration. VPA also enhanced early increases in the number of Ki-67(+) and growth-associated protein-43(+) cells during the regeneration of olfactory neuroepithelium. CONCLUSION: VPA administration promotes regeneration of olfactory sensory neurons in damaged neuroepithelium by stimulating the proliferation and differentiation of olfactory precursor cells. VPA has been used for several decades to safely treat neurological disorders. VPA may provide a new therapeutic strategy for the treatment of olfactory dysfunction caused by degeneration of the olfactory neuroepithelium.


Subject(s)
Anticonvulsants/administration & dosage , Olfaction Disorders/therapy , Olfactory Mucosa/pathology , Sensory Receptor Cells/drug effects , Valproic Acid/administration & dosage , Administration, Oral , Animals , Anticonvulsants/adverse effects , GAP-43 Protein/genetics , GAP-43 Protein/metabolism , Histone Acetyltransferases/antagonists & inhibitors , Humans , Ki-67 Antigen/metabolism , Male , Methimazole/toxicity , Mice , Mice, Inbred ICR , Nerve Regeneration , Olfaction Disorders/chemically induced , Olfactory Marker Protein/genetics , Olfactory Marker Protein/metabolism , Olfactory Mucosa/drug effects , Sensory Receptor Cells/pathology , Up-Regulation/drug effects , Valproic Acid/adverse effects
19.
Am J Rhinol Allergy ; 28(2): 103-9, 2014.
Article in English | MEDLINE | ID: mdl-24717945

ABSTRACT

BACKGROUND: Predominant eosinophil infiltration and tissue remodeling are common characteristics of chronic airway inflammation such as nasal polyposis and bronchial asthma. This study was designed to elucidate the role of eosinophils in tissue remodeling of chronic airway inflammation; eosinophil-epithelial interactions were examined by the coculture of airway epithelial cell line NCI-H292 with the eosinophilic cell line EoL-1 or with human blood eosinophils. METHODS: The coculture-induced production of MUC5AC mucin, platelet-derived growth factor AB (PDGF-AB), vascular endothelial growth factor (VEGF), transforming growth factor (TGF) beta1, and interleukin-8 (IL-8) were evaluated by enzyme-linked immunosorbent assay and reverse transcription-polymerase chain reaction. RESULTS: Eosinophil-epithelial interactions significantly stimulated the secretion of MUC5AC, PDGF-AB, VEGF, TGF-beta1, and IL-8 in culture supernatants. The epidermal growth factor receptor tyrosine kinase inhibitor AG1478 inhibited the coculture-induced secretion of MUC5AC, PDGF-AB, VEGF, and IL-8. Neutralizing antibodies directed against TGF-alpha or amphiregulin and pan-metalloproteinase inhibitor GM6001 inhibited the coculture-induced secretion of MUC5AC and amphiregulin from the cocultured NCI-H292 cells. Coculture of NCI-H292 cells with peripheral blood eosinophils also significantly stimulated MUC5AC production. CONCLUSION: The results of this study indicate that eosinophil-epithelial cell interactions are important in the pathogenesis of tissue remodeling of eosinophil-predominant airway inflammation such as occurs in nasal polyposis and bronchial asthma.


Subject(s)
Airway Remodeling , Asthma/immunology , Eosinophils/immunology , Epithelial Cells/immunology , Mucin 5AC/metabolism , Nasal Polyps/immunology , Respiratory System/pathology , Amphiregulin/pharmacology , Bodily Secretions/drug effects , Cell Communication/drug effects , Cell Communication/immunology , Cell Line , Coculture Techniques , Cytokines/metabolism , Dipeptides/pharmacology , Eosinophils/drug effects , Epithelial Cells/drug effects , ErbB Receptors/genetics , ErbB Receptors/metabolism , Fibrosis , Humans , Immunization , Quinazolines/pharmacology , Transcriptional Activation , Tyrphostins/pharmacology
20.
Ann Otol Rhinol Laryngol ; 122(11): 683-9, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24358628

ABSTRACT

OBJECTIVES: The resolution of inflammation is an active process controlled by several anti-inflammatory and pro-resolution mediators. Lipoxin A4, an endogenous lipid mediator, is a potential pro-resolution mediator that could attenuate inflammation. This study was conducted to elucidate the role of lipoxin A4 in upper airway inflammation. METHODS: Nasal secretions were collected from patients with chronic rhinosinusitis with nasal polyposis, patients with allergic rhinitis, and control subjects. The concentration of lipoxin A4 was measured by enzyme-linked immunosorbent assay. Nasal tissues were obtained from nasal polyps and inferior turbinates during endonasal surgery. The mRNA expressions of lipoxygenases (LOXs), lipoxin receptor (formyl peptide receptor-like 1; FPRL-1), and cysteinyl leukotriene type 1 receptor (CysLT1R) in nasal tissues were examined by reverse-transcription polymerase chain reaction. Tissue localization of FPRL-1 was determined by immunohistochemical staining. The in vitro effect of lipoxin A4 on airway epithelial cells was also examined. RESULTS: A significant concentration of lipoxin A4 was found in nasal secretions, and the concentration was increased in patients with allergic rhinitis. The mRNA expressions of 5-LOX, 15-LOX-1, FPRL-1, and CysLT1R were significantly greater in nasal polyps than in inferior turbinates. FPRL-1 was localized in nasal epithelial cells. Lipoxin A4 inhibited tumor necrosis factor alpha-induced interleukin 8 release from airway epithelial cells via its receptor FPRL-1. CONCLUSIONS: These results indicate that lipoxin A4 may play a role in the resolution of upper airway inflammation. A low concentration of lipoxin A4 may be involved in chronic inflammation of the upper airways.


Subject(s)
Gene Expression Regulation , Lipoxins/genetics , Nasal Polyps/genetics , RNA, Messenger/genetics , Rhinitis/genetics , Sinusitis/genetics , Adult , Aged , Cells, Cultured , Eicosanoids , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunohistochemistry , Lipoxins/biosynthesis , Male , Middle Aged , Nasal Mucosa/metabolism , Nasal Mucosa/pathology , Nasal Polyps/metabolism , Receptors, Formyl Peptide/biosynthesis , Receptors, Formyl Peptide/genetics , Receptors, Lipoxin/biosynthesis , Receptors, Lipoxin/genetics , Reverse Transcriptase Polymerase Chain Reaction , Rhinitis/metabolism , Rhinitis/pathology , Sinusitis/metabolism , Sinusitis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...